INNATE PHARMA (IPH.PA)

Every figure this model derived for IPH.PA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2024-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 391,000 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2024-12-31
cash 66,396,000 CashAndCashEquivalents 2025-01-01
current assets 85,742,000 CurrentAssets 2025-01-01
current liabilities 32,982,000 CurrentLiabilities 2025-01-01
equity 8,834,000 Equity 2025-01-01
interest expense 3,975,000 FinanceCosts 2024-12-31
ocf -6,896,000 CashFlowsFromUsedInOperatingActivities 2024-12-31
revenue 20,121,000 Revenue 2024-12-31
sbc 3,944,000 AdjustmentsForSharebasedPayments 2024-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up IPH.PA on one particular measure came for.

RatioValue
cash operating margin-236.72
current ratio2.6
current ratio reported2.6
fcf margin-36.22
interest cover-12.97
operating margin-256.32
owner earnings margin-55.82
revenue growth-67.36
revenue growth per share-67.36
rule of 40-323.68
sbc pct revenue19.6

What to be careful about

What this model itself distrusts about IPH.PA's figures. Written by the derivation as it ran, not added afterwards.